Why the study?
Can modified thrombelastography (TEG) be used as a rapid test to assess individual time-dependent clotting responses to aspirin and clopidogrel?
Can modified thrombelastography (TEG) be used as a rapid test to assess individual time-dependent clotting responses to aspirin and clopidogrel?
Modified thrombelastography using AUC15 and %CIn is a promising rapid point-of-care test to assess individual heterogeneity in response to antiplatelet therapy.
May support point-of-care assessment of antiplatelet heterogeneity; hypothesis-generating and should not yet change practice.
BACKGROUND: A rapid, reliable, point of care test reflecting patient specific responses to antiplatelet therapy would be of great clinical value in percutaneous coronary intervention (PCI). The aim of this study was to establish whether modified thrombelastography (TEG) can be employed as a 15 minute test of individual patient responses to aspirin and clopidogrel using a novel parameter, percentage clotting inhibition (%CIn). METHODS AND RESULTS: Thirty healthy volunteers and 10 patients undergoing elective PCI were recruited into four groups: 10 volunteers received a single 300 mg dose of aspirin [A1]: 10 volunteers received aspirin 75 mg daily for 7 days [A2]: 10 volunteers received a 600 mg dose of clopidogrel [C1]: 10 patients received a 600 mg loading dose of clopidogrel prior to elective PCI [C2]. In all cases the area under the clotting response curve was measured at 15 minutes (AUC15) and used to calculate a novel parameter, percentage clotting inhibition (%CIn). Large differences were demonstrated in both aspirin and clopidogrel groups in response to therapy as assessed by both the area under the curve at 15 minutes and %CIn. Furthermore, the technique demonstrated important heterogeneity of time-dependent responses between individuals. CONCLUSION: Modified TEG, employing AUC15 and %CIn, is a promising tool for assessing responses to aspirin and clopidogrel. Further data are now required to assess the potential of this test to optimise individual therapy in PCI patients in order to detect and treat those patients with relative hypo-responsiveness to anti-platelet drugs.
No takes yet. Share an insight, caveat, or question.
Hobson et al. (2007) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: